|
As
of June 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
37,083 |
|
| Shares from the conversion of convertible notes and accrued interest |
|
|
78,584 |
|
| Shares from the conversion of Series A Stock inclusive of cumulative dividends |
|
|
110,437 |
|
| Shares from the conversion of Series B Preferred Stock inclusive of dividends |
|
|
271,490 |
|
As
of June 30, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
| Shares from common stock options |
|
|
11,715 |
|
| Shares from common stock warrants |
|
|
187,339 |
|
| Shares from the conversion of debentures |
|
|
5,469 |
|
| Shares from the conversion of Series A Stock |
|
|
75,000 |
|
| Shares from the conversion of Series B Preferred Stock |
|
|
390,625 |
|
| Shares from the conversion of Series E-1 Preferred Stock |
|
|
212,500 |
|
|